Monkeypox Treatment Market

Monkeypox Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Monkeypox Treatment Market

• Demand and Growth Drivers
  • Antiviral therapeutics, led by tecovirimat (TPOXX), remain the primary treatment approach for monkeypox, with ongoing stockpiling programs sustaining procurement demand across public health systems.
  • Vaccination programs using MVA-BN (Jynneos/Imvanex) for pre-exposure and post-exposure prophylaxis are creating recurring procurement cycles linked to outbreak surveillance and public health preparedness.
  • Clinical trial activity evaluating new antiviral compounds and combination regimens is expanding the treatment pipeline beyond the current limited pharmacopeia for orthopoxvirus infections.
• Product and Segment View
  • Therapeutic is expected to hold 68.4% of the Treatment Type segment in 2026.
  • Oral is expected to hold 52.0% of the Administration segment in 2026.
  • Pharmaceutical Therapy is expected to hold 46.5% of the Technology segment in 2026.
• Geography and Competitive Outlook
  • USA is expected to lead growth at 10.5%, supported by the largest biodefense stockpiling program and clinical trial infrastructure.
  • South Korea follows at 10.4%, driven by infectious disease preparedness investment and clinical research capacity.
  • SIGA Technologies Inc. and established players compete on antiviral portfolio and vaccine platform.
• Analyst Opinion
  • The Monkeypox Treatment Market is evolving as new technologies and treatment approaches expand beyond established product categories.
  • Regulatory developments and reimbursement frameworks are shaping adoption patterns and competitive dynamics across key markets.
  • Companies that combine antiviral portfolio with vaccine platform are expected to gain procurement share over the forecast period.
  • Emerging technologies and pipeline developments are creating opportunities for both established players and new market entrants.

Key Takeaways, Market Size, and Forecast

• The monkeypox treatment market is projected to grow from USD 125.5 million in 2026 to USD 325.4 million by 2036, at a CAGR of 10.0%.
• The market was valued at USD 114.06 million in 2025.
• By 2036, the market is expected to reach approximately USD 325.43 million.
• From 2026 to 2036, the market is projected to expand at a CAGR of 10.0%.
• The market is expected to create an incremental opportunity of USD 199.96 million between 2026 and 2036.
• In 2026, therapeutic treatments are expected to account for 68.4% of the treatment type segment, driven by clinical reliance on antiviral therapeutics for symptomatic management and public health vaccination programs.
• The USA (10.5%) and South Korea (10.4%) are among the fastest-growing markets globally.

Monkeypox Treatment Market Definition

The Monkeypox Treatment Market covers therapeutic products, prophylactic vaccines, immunoglobulin therapies, and supportive care products used for the treatment and prevention of monkeypox (mpox) infections.

Monkeypox Treatment Market Inclusions

Market scope covers all commercially available products and services categorized by treatment type (Treatment Type, Therapeutic, Prophylactic Vaccines), administration (Administration, Oral, Injectable), technology (Technology, Pharmaceutical Therapy, Biotechnology-Based Therapy, Genetic Engineering-Based Therapy), treatment category (Treatment Category, Antiviral Medications, Vaccination, Immunoglobulin Therapy, Supportive Care), end user (End User, Hospitals, Specialty Clinics, Research Institutes), distribution channel (Distribution Channel, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). Revenue coverage spans the 2026 to 2036 forecast period.

Monkeypox Treatment Market Exclusions

The scope does not include general antiviral products not indicated for orthopoxvirus infections, diagnostic test kits, or infection control equipment not classified as therapeutic products.

Monkeypox Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with industry stakeholders and procurement decision-makers across key markets.
• Desk Research: Combined data from regulatory filings, industry publications, clinical and trade databases, and manufacturer disclosures.
• Market sizing and forecasting: Bottom-up aggregation across segments and regions, with adoption velocity modeling and cross-validation against industry benchmarks.
• Data validation: Cross-checked quarterly against industry production data, regulatory databases, and manufacturer disclosures.

Why is the Monkeypox Treatment Market Growing?

• Therapeutic interventions account for 68.4% of the treatment type segment, reflecting the clinical need for antiviral management in confirmed monkeypox cases with moderate to severe presentations.
• Antiviral medications hold 52.0% of the treatment category, with tecovirimat and brincidofovir representing the primary therapeutic options approved or available under emergency protocols.
• USA leads growth at 10.5%, supported by the largest biodefense stockpiling program and clinical trial infrastructure.

The Monkeypox Treatment Market is growing as public health systems maintain preparedness programs following the 2022 to 2024 outbreak cycle. Therapeutic products account for 68.4% of the treatment type segment, with prophylactic vaccines contributing the preventive component. Oral administration leads at 52.0%, reflecting the preference for tecovirimat tablet formulations in outpatient management. Pharmaceutical therapy holds 46.5% of the technology segment, with biotechnology-based and genetic engineering-based therapies representing emerging modalities.

Antiviral medications account for 48.5% of the treatment category, with vaccination, immunoglobulin therapy, and supportive care serving distinct clinical roles. Hospitals lead end-user demand at 49.0%, with infectious disease clinics and research institutes contributing additional procurement volume. Hospital pharmacies hold 44.0% of distribution, consistent with the specialist prescribing and institutional dispensing patterns for orthopoxvirus treatments.

Public health stockpiling programs in the US, EU, and Japan are a structural demand driver, creating government procurement volumes that are linked to pandemic preparedness budgets rather than active case counts. Clinical trial activity for next-generation antivirals is expanding the pipeline, with several compounds in Phase I and Phase II development targeting improved efficacy and reduced side effect profiles.

Market Segmentation Analysis

• Therapeutic holds 68.4% of the Treatment Type segment in 2026.
• Oral accounts for 52.0% of the Administration segment.

The Monkeypox Treatment Market is organized across 6 segmentation dimensions: Treatment Type, Administration, Technology, Treatment Category, End User, Distribution Channel.

Insights into the Therapeutic Treatment Type Segment

In 2026, Therapeutic is expected to account for 68.4% of the Treatment Type segment. Key sub-categories include Tecovirimat, Brincidofovir, Cidofovir.

Therapeutic holds 68.4% of the segment, contributing to segment diversity.

Insights into the Pharmaceutical Therapy Technology Segment

In 2026, Pharmaceutical Therapy is expected to account for 46.5% of the Technology segment. Key sub-categories include Small Molecule Drugs.

Pharmaceutical Therapy holds 46.5% of the segment, contributing to segment diversity.

Monkeypox Treatment Market Drivers, Restraints, and Opportunities

• Government health agencies maintain strategic stockpiles of tecovirimat and MVA-BN vaccine as part of biodefense and pandemic preparedness programs.
• The monkeypox treatment pharmacopeia is narrow, with tecovirimat as the primary approved antiviral and brincidofovir and cidofovir available under emergency or compassionate use protocols.
• Pre-exposure vaccination for high-risk populations and post-exposure ring vaccination during outbreaks create recurring procurement demand for MVA-BN (Jynneos/Imvanex).

The Monkeypox Treatment Market is shaped by clinical demand, technology development, regulatory frameworks, and access dynamics. Growth reflects the balance between demand drivers and adoption constraints.

Stockpiling and Preparedness Procurement

Government health agencies maintain strategic stockpiles of tecovirimat and MVA-BN vaccine as part of biodefense and pandemic preparedness programs. This procurement is budget-driven and occurs independently of active outbreak levels, providing baseline demand stability.

Limited Treatment Options and Pipeline Activity

The monkeypox treatment pharmacopeia is narrow, with tecovirimat as the primary approved antiviral and brincidofovir and cidofovir available under emergency or compassionate use protocols. Clinical trials evaluating new antiviral compounds and combination regimens are expanding the development pipeline.

Vaccination Program Expansion

Pre-exposure vaccination for high-risk populations and post-exposure ring vaccination during outbreaks create recurring procurement demand for MVA-BN (Jynneos/Imvanex). Vaccine supply constraints and cold chain requirements influence distribution patterns across regions.

Outbreak Cycle Dependency

Demand for therapeutics and diagnostics is influenced by monkeypox outbreak cycles, creating volume variability. Sustained endemic transmission in certain regions and periodic outbreaks in non-endemic countries maintain ongoing clinical demand above pre-2022 levels.

Analysis of Monkeypox Treatment Market By Key Countries

Source: FMI analysis based on primary research and proprietary forecasting model

• USA at 10.5% is supported by the largest biodefense stockpiling program and clinical trial infrastructure.
• South Korea at 10.4% is supported by infectious disease preparedness investment and clinical research capacity.
• Japan at 10.3% is supported by biodefense procurement and advanced infectious disease treatment infrastructure.
• EU at 10.2% is supported by harmonized procurement frameworks and ECDC coordination for outbreak response.

The global Monkeypox Treatment Market is projected to expand at a CAGR of 10.0% from 2026 to 2036. The analysis covers more than 30 countries.

Demand Outlook for Monkeypox Treatment Market in the United States

The United States is projected to grow at 10.5% through 2036. The largest biodefense stockpiling program and clinical trial infrastructure are the primary factors shaping demand.

• The largest biodefense stockpiling program and clinical trial infrastructure supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks support market development.

Future Outlook for Monkeypox Treatment Market in the United Kingdom

The United Kingdom is projected to grow at 9.8% through 2036. NHS infectious disease treatment programs and public health preparedness are the primary factors shaping demand.

• NHS infectious disease treatment programs and public health preparedness supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks support market development.

Opportunity Analysis of Monkeypox Treatment Market in Japan

Japan is projected to grow at 10.3% through 2036. Biodefense procurement and advanced infectious disease treatment infrastructure are the primary factors shaping demand.

• Biodefense procurement and advanced infectious disease treatment infrastructure supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks support market development.

In-depth Analysis of Monkeypox Treatment Market in the European Union

The European Union is projected to grow at 10.2% through 2036. Harmonized procurement frameworks and ECDC coordination for outbreak response are the primary factors shaping demand.

• Harmonized procurement frameworks and ECDC coordination for outbreak response supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks support market development.

Sales Analysis of Monkeypox Treatment Market in South Korea

South Korea is projected to grow at 10.4% through 2036. Infectious disease preparedness investment and clinical research capacity are the primary factors shaping demand.

• Infectious disease preparedness investment and clinical research capacity supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks support market development.

Competitive Landscape and Strategic Positioning

• SIGA Technologies Inc. holds a leading position based on antiviral portfolio and vaccine platform.
• Established players compete on antiviral portfolio, vaccine platform, stockpiling contracts, geographic footprint.
• Emerging players are focusing on specialized capabilities and niche market positioning.

SIGA Technologies Inc. holds a leading position through its antiviral portfolio and vaccine platform. Chimerix, Inc. maintains a strong position through complementary capabilities.

Bavarian Nordic, Sanofi SA, Emcure Pharmaceuticals compete on specialized capabilities and Geographic Footprint. These companies serve distinct market segments through targeted strategies.

Market entry requires investment in antiviral portfolio, regulatory compliance, and distribution infrastructure. Established companies benefit from customer relationships and track records.

Key Companies in the Monkeypox Treatment Market

Key global companies leading the monkeypox treatment market include:

• SIGA Technologies Inc., Chimerix, Inc., Bavarian Nordic, Sanofi SA are the established market leaders with broad capabilities across antiviral portfolio and vaccine platform.
• Emcure Pharmaceuticals, Jinan Jinda Pharmaceutical Chemistry Co., Ltd., Emergent Pharmaceuticals have built regional positions through specialized capabilities.
• Gilead Sciences, Inc., Hetero, Piramal Pharma Solutions are entering through niche specialization and technology-driven differentiation.

Competitive Benchmarking: Monkeypox Treatment Market

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Monkeypox Treatment Market

• In 2025, SIGA Technologies Inc. expanded its antiviral portfolio capabilities across key markets.
• In 2025, Chimerix, Inc. launched new offerings targeting vaccine platform requirements.

Key Players in the Monkeypox Treatment Market:

Major Global Players:

• SIGA Technologies Inc.
• Chimerix, Inc.
• Bavarian Nordic
• Sanofi SA
• Emcure Pharmaceuticals
• Jinan Jinda Pharmaceutical Chemistry Co., Ltd.
• Emergent Pharmaceuticals

Emerging Players/Startups

• Gilead Sciences, Inc.
• Hetero
• Piramal Pharma Solutions

Report Scope and Coverage

Monkeypox Treatment Market Segmentation

Monkeypox Treatment Market Market Segmented by Treatment Type:

• Therapeutic
  • Tecovirimat
  • Brincidofovir
  • Cidofovir
• Prophylactic Vaccines
  • Preventive Immunization

Monkeypox Treatment Market Market Segmented by Administration:

• Oral
  • Tablet Formulations
  • Capsule Formulations
• Injectable
  • Intravenous Administration
  • Intramuscular Administration

Monkeypox Treatment Market Market Segmented by Technology:

• Pharmaceutical Therapy
  • Small Molecule Drugs
• Biotechnology-Based Therapy
  • Biologic Agents
• Genetic Engineering-Based Therapy
  • Recombinant Platforms

Monkeypox Treatment Market Market Segmented by Treatment Category:

• Antiviral Medications
  • DNA Polymerase Inhibitors
  • Viral Envelope Inhibitors
• Vaccination
  • Live Attenuated Vaccines
  • Non-Replicating Vaccines
• Immunoglobulin Therapy
  • Passive Immunization
• Supportive Care
  • Symptom Management

Monkeypox Treatment Market Market Segmented by End User:

• Hospitals
  • Inpatient Care Units
  • Isolation Units
• Specialty Clinics
  • Infectious Disease Clinics
• Research Institutes
  • Clinical Research Centers

Monkeypox Treatment Market Market Segmented by Distribution Channel:

• Hospital Pharmacies
  • Institutional Supply
• Retail Pharmacies
  • Prescription Dispensing
• Online Pharmacies
  • Digital Health Platforms

Monkeypox Treatment Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO Monkeypox Strategic Preparedness, Readiness, and Response Plan. WHO.
• 2. USA Centers for Disease Control and Prevention. (2024). CDC Monkeypox Clinical Guidance and Treatment Protocols. CDC.
• 3. European Medicines Agency. (2024). EMA Assessment Report: Tecovirimat for Orthopoxvirus Infections. EMA.
• 4. USA Food and Drug Administration. (2024). FDA Emergency Use Authorization: Monkeypox Countermeasures. FDA.
• 5. National Institutes of Health. (2024). NIH Clinical Trials Registry: Monkeypox Treatment Studies. NIH.
• 6. European Centre for Disease Prevention and Control. (2024). ECDC Monkeypox Surveillance and Epidemiological Report. ECDC.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the size of the market and revenue from 2026 to 2036.
• Segmentation by Treatment Type, Administration, Technology, Treatment Category, End User, Distribution Channel, and region.
• Insights about more than 30 markets across regions.
• Technology and treatment landscape analysis.
• Assessment of the competitive landscape.
• Finding investment opportunities across segments and regions.
• Supply chain and distribution analysis.
• Delivery of data in PDF and Excel formats.